Alumis
Dennis Leventis is an accomplished IT professional with extensive experience in information technology management. Currently serving as the Associate Director of Information Technology at Alumis since January 2022, Dennis previously held positions at Principia Biopharma and Actelion, where responsibilities included managing business applications, customer support, and IT service operations. With a strong focus on enhancing customer satisfaction and service delivery, Dennis has successfully led teams and implemented processes to improve IT support systems. Dennis began the career in 2005 as an IT Service Desk Technician at Cotherix, demonstrating proficiency in service desk operations and technical support. Educationally, Dennis holds a Bachelor of Applied Science in Computer Science from San Francisco State University.
This person is not in any teams
This person is not in any offices
Alumis
2 followers
At Alumis, our goal is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. We recognize that patients living with immune-mediated diseases need alternatives to currently available therapies. Despite recent advances and innovations in the treatment of immune-mediated diseases, many patients continue to suffer, cycling through currently approved therapies while looking for a solution that alleviates the debilitating impact of their disease without life-limiting side effects. Addressing the needs of these patients is why we exist. We are pioneering a precision approach that leverages insights we derive from powerful data analytics to select the right target, right molecule, right indication, right patient, and right endpoint resulting in optimized outcomes for patients. We believe that combining our insights with an integrated approach to drug development will produce the next generation of treatments to address immune dysfunction. Incubated by Foresite Labs, Alumis is led by a team of deeply experienced professionals who are devoted to transforming the lives of patients with immune-mediated diseases by developing a pipeline of transformative therapies.